Search

Your search keyword '"Porst, H"' showing total 37 results
Start Over Author "Porst, H" Publisher elsevier bv
37 results on '"Porst, H"'

8. 211 Sexual dysfunction, aging male symptoms and their relationship to testosterone (T) in the Registry of Hypogonadism in Men (RHYME)

Author

Rosen, R.C., primary, Arver, S., additional, Behre, H.M., additional, Chang, R., additional, Curto, T., additional, Jones, T.H., additional, Maggi, M., additional, Martha, J., additional, Martin-Morales, A., additional, Meuleman, E.J., additional, Porst, H., additional, Wu, F.C.W., additional, and Araujo, A.B., additional

Published
2013
Full Text
View/download PDF

37. Systematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms

Author

Claudius Füllhase, Christopher Chapple, Jean-Nicolas Cornu, Cosimo De Nunzio, Christian Gratzke, Steven A. Kaplan, Michael Marberger, Francesco Montorsi, Giacomo Novara, Matthias Oelke, Hartmut Porst, Claus Roehrborn, Christian Stief, Kevin T. McVary, Fullhase, C, Chapple, C, Cornu, Jn, De Nunzio, C, Gratzke, C, Kaplan, Sa, Marberger, M, Montorsi, Francesco, Novara, G, Oelke, M, Porst, H, Roehrborn, C, Stief, C, and Mcvary, Kt

Subjects
Male, medicine.medical_specialty, Time Factors, Combination therapy, Urology, Prostatic Hyperplasia, Muscarinic Antagonists, 5-alpha Reductase Inhibitors, Lower Urinary Tract Symptoms, Lower urinary tract symptoms, Prostate, medicine, Humans, Adverse effect, 5 alpha-reductase inhibitors, Evidence-Based Medicine, Prostatic hyperplasia, Adrenergic alpha(1)-receptor antagonists, Muscarinic antagonists, business.industry, Clinical study design, Antagonist, Phosphodiesterase 5 Inhibitors, medicine.disease, 5α-reductase inhibitors, lower urinary tract symptoms, muscarinic antagonists, prostatic hyperplasia, Surgery, Clinical trial, Treatment Outcome, medicine.anatomical_structure, Overactive bladder, Adrenergic alpha-1 Receptor Antagonists, Drug Therapy, Combination, business
Abstract

Background: Several drugs are approved for the treatment of lower urinary tract symptoms (LUTS) in men, but these are mostly used by clinicians as monotherapies. The combination of different compounds, each of which targets a different aspect of LUTS, seems appealing. However, only few clinical trials have evaluated the effects of combination therapies. Objective: This systematic review analyzes the efficacy and adverse events of combination therapies for male LUTS. Evidence acquisition: PubMed and Cochrane databases were used to identify clinical trials and meta-analyses on male LUTS combination therapy. The search was restricted to studies of level of evidence >= 1b. A total of 49 papers published between January 1988 and March 2012 were identified. Evidence synthesis: The alpha(1)-adrenoceptor antagonist (alpha(1)-blocker)/5 alpha-reductase inhibitor (5-ARI) combination provides the most data. This combination seems to be more efficacious in terms of several outcome variables in patients whose prostate volume is between 30 ml and 40 ml when treatment is maintained for >1 yr; when given for 6 yr. The alpha(1)-blocker/muscarinic receptor antagonist (antimuscarinic) combination was most frequently assessed as an add-on therapy to already existing alpha(1)-blocker therapy. Inconsistent data derive from heterogeneous study populations and different study designs. Currently, the alpha(1)-blocker/antimuscarinic combination appears to be a second-line add-on for patients with insufficient symptom relief after monotherapy. The combination seems to be safe in men with postvoid residual 4 mo concerning safety and efficacy of this combination. The alpha(1)-blocker/phosphodiesterase type 5 inhibitor combination is a new treatment option with only preliminary reports. More studies are needed before definitive conclusions can be drawn. Conclusions: An alpha(1)-blocker/5-ARI combination is beneficial for patients whose prostate volume is between 30 ml and 40 ml when medical treatment is intended for >1 yr. Based on short-term follow-up studies, add-on of antimuscarinics to alpha(1)-blockers is an option when postvoid residual is

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results